Supernatant Metabolites from Halophilic Archaea to Reduce Tumorigenesis in Prostate Cancer In-vitro and In-vivo

• Published in: Iranian journal of pharmaceutical research : IJPR 2019-01, Vol.18 (1), p.241-253
• Main Authors: Safarpour, Atefeh, Ebrahimi, Marzieh, Shahzadeh Fazeli, Seyed Abolhassan, Amoozegar, Mohammad Ali
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 1735-0328; 1726-6890

Halophilic archaea are known as the novel producers of natural products and their supernatant metabolites could have cytotoxic effects on cancer cells. In the present study, we screened the anticancer potential of supernatant metabolites from eight native haloarchaeal strains obtained from a culture collection in Iran. Five human cancer cell lines including breast, lung, prostate and also human fibroblast cells as the normal control were used in the present study. Moreover, to evaluate the anti-tumor effect of the selected supernatant, inhibition of sphere formation and tumor development was assessed and , respectively. Among all strains, supernatant metabolites from IBRC M10715 had the most potent cytotoxic effect on prostate cancer cell lines (IC50 = 0.5 mg/mL) without any effects on normal cells. It significantly increased both early and late apoptosis (about 11% and 9%, respectively) in the androgen-dependent PC3 cell line, reduced sphere formation ability of DU145 and PC3 cells with down-regulation of gene expression. Furthermore, our results revealed that tumors developed in nude mice significantly shrank post intratumor injection of metabolites of the haloarchaeal strain. In conclusion, we suggested here for the first time that supernatant metabolites from IBRC M10715 could be a novel component against prostate cancer and with remarkable reduction in stem-like properties of tumor.